Display options
Cite
da Silva Lopes L, Silva RO, de Sousa Lima G, et al. Is there a common pathophysiological mechanism between COVID-19 and depression?. Acta Neurol Belg. 2021;121(5):1117-1122doi: 10.1007/s13760-021-01748-5.
da Silva Lopes, L., Silva, R. O., de Sousa Lima, G., de Araújo Costa, A. C., Barros, D. F., & Silva-Néto, R. P. (2021). Is there a common pathophysiological mechanism between COVID-19 and depression?. Acta neurologica Belgica, 121(5), 1117-1122. https://doi.org/10.1007/s13760-021-01748-5
da Silva Lopes, Luciano, et al. "Is there a common pathophysiological mechanism between COVID-19 and depression?." Acta neurologica Belgica vol. 121,5 (2021): 1117-1122. doi: https://doi.org/10.1007/s13760-021-01748-5
da Silva Lopes L, Silva RO, de Sousa Lima G, de Araújo Costa AC, Barros DF, Silva-Néto RP. Is there a common pathophysiological mechanism between COVID-19 and depression?. Acta Neurol Belg. 2021 Oct;121(5):1117-1122. doi: 10.1007/s13760-021-01748-5. Epub 2021 Jul 29. PMID: 34327666; PMCID: PMC8321009.
Copy Download .nbib Format: NLM
Share it on

Acta Neurol Belg. 2021 Oct;121(5):1117-1122. doi: 10.1007/s13760-021-01748-5. Epub 2021 Jul 29.

Is there a common pathophysiological mechanism between COVID-19 and depression?.

Acta neurologica Belgica

Luciano da Silva Lopes, Raquel Oliveira Silva, Guilherme de Sousa Lima, Arthur Caminha de Araújo Costa, Daniela França Barros, Raimundo Pereira Silva-Néto

Affiliations

  1. Department of Biophysics and Physiology, Postgraduate Programs in Pharmaceutical Sciences and Laboratory of Research in Experimental Neurochemistry (LAPNEX), Teresina, Brazil.
  2. Federal University of Piauí, Teresina, Brazil.
  3. Federal University of Delta of Parnaíba, Parnaíba, Piauí, 64001-020, Brazil.
  4. Federal University of Delta of Parnaíba, Parnaíba, Piauí, 64001-020, Brazil. [email protected].

PMID: 34327666 PMCID: PMC8321009 DOI: 10.1007/s13760-021-01748-5

Abstract

COVID-19 is a disease caused by SARS-CoV-2 and was initially considered to cause serious damage to the respiratory system. Over time, it has been found to affect other organs due to its ability to bind to the ACE2 receptor (type 2 angiotensin-converting enzyme), which can be found in various tissues, including the central nervous system. In addition, a large formation of pro-inflammatory cytokines responsible for various lesions was observed during the evolution of this disease. Our objective was to demonstrate the molecular mechanisms involved in the infection that may demonstrate the relationship between COVID-19 and the development of depressive conditions. Based on the main medical databases (LiLacs, SciELO, Bireme, Scopus, EBSCO, and PubMed) and using the terms 'coronavirus infections' AND 'Inflammation' AND 'depression' AND 'cytokines', we conducted an integrative review of articles published in 2020. Considering this stage of Covid-19 and the inflammatory component of depression, this review showed a relationship between these two conditions based on common pathophysiological mechanisms indicating possible depressive disorders in surviving patients, especially in the most severe cases. The role of inflammatory cytokines and the presence of ACE-2 receptors on the cell surface appear to be the common pathophysiological mechanism between COVID-19 and depression.

© 2021. Belgian Neurological Society.

Keywords: COVID-19; Coronavirus infections; Cytokines; Depression; Inflammation

References

  1. Bulut C, Kato Y (2020) Epidemiology of COVID-19. Turk J Med Sci 50(1):563–570 - PubMed
  2. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J et al (2020) Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol 30(3):313–324 - PubMed
  3. Huang X, Wei F, Hu L, Wen L, Chen K (2020) Epidemiology and clinical characteristics of COVID-19. Arch Iran Med 23(4):268–271 - PubMed
  4. Faro A, Bahiano MA, Nakano TC, Reis C, Silva BFP, Vitti LS (2020) COVID-19 e saúde mental: a emergência do cuidado. Estud Psicol (Campinas) 37:e200074 - PubMed
  5. Breithaupt-Faloppa AC, Correia CJ, Prado CM, Stilhano RS, Ureshino RP, Moreira LFP (2020) 17β-Estradiol, a potential ally to alleviate SARS-CoV-2 infection. Clinics 75:e1980 - PubMed
  6. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ et al (2020) The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res 7:11 - PubMed
  7. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P et al (2020) Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 7(7):611–627 - PubMed
  8. Harenberg J, Favaloro E (2020) COVID-19: progression of disease and intravascular coagulation - present status and future perspectives. Clin Chem Lab Med 58(7):1029–1036 - PubMed
  9. Wong SH, Lui RN, Sung JJ (2020) Covid-19 and the digestive system. J Gastroenterol Hepatol 35(5):744–748 - PubMed
  10. Troyer EA, Kohn JN, Hong S (2020) Are we facing a crashing wave of neuropsychiatric sequelae of COVID-1? Neuropsychiatric symptoms and potential immunologic mechanism. Brain Behav Immun 87:34–39 - PubMed
  11. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L et al (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 87:18–22 - PubMed
  12. Shao O, Herrlinger S, Zhu YN, Yang M, Goodfellow F, Stice S et al (2017) The African Zika virus MR-766 is more virulent and causes more severe brain damage than current Asian lineage and dengue virus. Development 144(22):4114–4124 - PubMed
  13. Fletcher NF, McKeating JA (2012) Hepatitis C virus and the brain. J Viral Hepat 19(5):301–306 - PubMed
  14. Severance EG, Dickerson FB, Yolken RH (2018) Autoimmune phenotypes in schizophrenia reveal novel treatment targets. Pharmacol Ther 189:184–198 - PubMed
  15. Hascup ER, Hascup KN (2020) Does SARS-CoV-2 infection cause chronic neurological complications? Geroscience 42(4):1083–1087 - PubMed
  16. Li H, Xue Q, Xu X (2020) Involvement of the Nervous System in SARS-CoV-2 Infection. Neurotox Res. https://doi.org/10.1007/s12640-020-00219-8 - PubMed
  17. Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, Reyes-Bueno JÁ, Petersen NC, Aguilar-Castillo MJ et al (2020) Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurologia 35(4):245–251 - PubMed
  18. Taquet M, Geddes JR, Husain M, Luciano S (2021) 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8(5):416–427 - PubMed
  19. Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci 413:116832 - PubMed
  20. Singha T (2020) A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 87(4):281–286 - PubMed
  21. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z et al (2020) Characteristics of COVID-19 infection in Beijing. J Infect 80(4):401–406 - PubMed
  22. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W et al (2020) Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 12(4):372 - PubMed
  23. Ye Q, Wang B, Mao J (2020) The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect 80(6):607–613 - PubMed
  24. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S (2020) Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 39(7):2085–2094 - PubMed
  25. Haidar MA, Jourdi H, Hassan ZH, Ashekyan O, Fardoun M, Wehbe Z et al (2020) Neurological and neuropsychological changes associated with SARS-CoV-2 infection: New observations, new mechanisms. Neuroscientist. https://doi.org/10.1177/1073858420984106 - PubMed
  26. Mahalakshmi AM, Ray B, Tuladhar S, Bhat A, Paneyala S, Patteswari D et al (2021) Does COVID-19 contribute to development of neurological disease? Immun Inflamm Dis 9(1):48–58 - PubMed
  27. Malhi GS, Mann JJ (2018) Depression. Lancet 392:2299–2312 - PubMed
  28. Dean J, Keshavan M (2017) The neurobiology of depression: An integrated view. Asian J Psychiatr 27:101–111 - PubMed
  29. Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH et al (2002) The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 7(10):1107–1114 - PubMed
  30. Nestler E, Barrot M, Di Leone R, Eisch A, Gold S, Monteggia L (2002) Neurobiology of depression. Neuron 34(1):13–25 - PubMed
  31. Miller AH, Maletic V, Raison CL (2009) Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression. Biol Psychiatry 65(9):732–741 - PubMed
  32. Halaris A (2019) Inflammation and depression but where does the inflammation come from? Curr Opin Psychiatry 32(5):422–428 - PubMed
  33. Rhie SJ, Jung EY, Shim I (2020) The role of neuroinflammation on pathogenesis of affective disorders. J Exerc Rehabil 16(1):2–9 - PubMed
  34. Vian J, Pereira C, Chavarria V, Köhler C, Stubbs B, Quevedo J et al (2017) The renin–angiotensin system: A possible new target for depression. BMC Med 15(1):144 - PubMed
  35. Velasco-Fargas R, Martínez-Hernández E (2020) Mecanismos fisiopatogénicos de afectación neurológica. In: Porta-Etessam J et al. Manual COVID-19 para el neurólogo general. Madrid: Ediciones SEN. - PubMed
  36. Felger JC, Lotrich FE (2013) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246:199–229 - PubMed

MeSH terms

Publication Types